nodes	percent_of_prediction	percent_of_DWPC	metapath
Captopril—systemic scleroderma—ankylosing spondylitis	0.745	1	CtDrD
Captopril—ALB—Prednisone—ankylosing spondylitis	0.0232	0.182	CbGbCtD
Captopril—ABCB1—Methylprednisolone—ankylosing spondylitis	0.0201	0.157	CbGbCtD
Captopril—SLC22A6—Methotrexate—ankylosing spondylitis	0.0137	0.107	CbGbCtD
Captopril—ABCB1—Betamethasone—ankylosing spondylitis	0.013	0.102	CbGbCtD
Captopril—ABCB1—Prednisolone—ankylosing spondylitis	0.0129	0.101	CbGbCtD
Captopril—ABCB1—Prednisone—ankylosing spondylitis	0.0122	0.0953	CbGbCtD
Captopril—ALB—Methotrexate—ankylosing spondylitis	0.0117	0.0914	CbGbCtD
Captopril—MMP9—synovial fluid—ankylosing spondylitis	0.0115	0.193	CbGeAlD
Captopril—F2—knee—ankylosing spondylitis	0.00901	0.152	CbGeAlD
Captopril—MMP2—skeletal joint—ankylosing spondylitis	0.00852	0.143	CbGeAlD
Captopril—ABCB1—Dexamethasone—ankylosing spondylitis	0.00759	0.0595	CbGbCtD
Captopril—MMP9—skeletal joint—ankylosing spondylitis	0.00741	0.125	CbGeAlD
Captopril—CYP2D6—Dexamethasone—ankylosing spondylitis	0.00715	0.0561	CbGbCtD
Captopril—ABCB1—Methotrexate—ankylosing spondylitis	0.0061	0.0478	CbGbCtD
Captopril—MMP2—cartilage tissue—ankylosing spondylitis	0.00573	0.0964	CbGeAlD
Captopril—F2—vertebral column—ankylosing spondylitis	0.00514	0.0865	CbGeAlD
Captopril—MMP9—cartilage tissue—ankylosing spondylitis	0.00498	0.0839	CbGeAlD
Captopril—ACE—skeletal joint—ankylosing spondylitis	0.00395	0.0665	CbGeAlD
Captopril—LTA4H—tendon—ankylosing spondylitis	0.00138	0.0232	CbGeAlD
Captopril—MMP2—tendon—ankylosing spondylitis	0.000979	0.0165	CbGeAlD
Captopril—MMP9—tendon—ankylosing spondylitis	0.000852	0.0143	CbGeAlD
Captopril—MMP9—Validated targets of C-MYC transcriptional activation—KIR3DL1—ankylosing spondylitis	0.000499	0.0869	CbGpPWpGaD
Captopril—MMP2—Matrix Metalloproteinases—MMP3—ankylosing spondylitis	0.00036	0.0627	CbGpPWpGaD
Captopril—MMP2—Activation of Matrix Metalloproteinases—MMP3—ankylosing spondylitis	0.000342	0.0596	CbGpPWpGaD
Captopril—MMP2—Collagen degradation—MMP3—ankylosing spondylitis	0.000298	0.0519	CbGpPWpGaD
Captopril—MMP2—Dexamethasone—Methylprednisolone—ankylosing spondylitis	0.000259	0.105	CbGdCrCtD
Captopril—MMP2—Betamethasone—Methylprednisolone—ankylosing spondylitis	0.000259	0.105	CbGdCrCtD
Captopril—MMP2—Dexamethasone—Betamethasone—ankylosing spondylitis	0.000255	0.104	CbGdCrCtD
Captopril—MMP2—Betamethasone—Dexamethasone—ankylosing spondylitis	0.000255	0.104	CbGdCrCtD
Captopril—MMP2—Betamethasone—Triamcinolone—ankylosing spondylitis	0.000249	0.101	CbGdCrCtD
Captopril—MMP2—Dexamethasone—Triamcinolone—ankylosing spondylitis	0.000249	0.101	CbGdCrCtD
Captopril—MMP9—Endochondral Ossification—RUNX3—ankylosing spondylitis	0.000245	0.0427	CbGpPWpGaD
Captopril—MMP2—Betamethasone—Prednisone—ankylosing spondylitis	0.000236	0.0961	CbGdCrCtD
Captopril—MMP2—Dexamethasone—Prednisone—ankylosing spondylitis	0.000236	0.0961	CbGdCrCtD
Captopril—MMP9—Matrix Metalloproteinases—MMP3—ankylosing spondylitis	0.000236	0.0411	CbGpPWpGaD
Captopril—MMP2—Dexamethasone—Prednisolone—ankylosing spondylitis	0.000231	0.0938	CbGdCrCtD
Captopril—MMP2—Betamethasone—Prednisolone—ankylosing spondylitis	0.000231	0.0938	CbGdCrCtD
Captopril—MMP9—Activation of Matrix Metalloproteinases—MMP3—ankylosing spondylitis	0.000224	0.0391	CbGpPWpGaD
Captopril—MMP9—Collagen degradation—MMP3—ankylosing spondylitis	0.000195	0.0341	CbGpPWpGaD
Captopril—MMP9—Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling—MMP3—ankylosing spondylitis	0.00018	0.0314	CbGpPWpGaD
Captopril—Polyuria—Methotrexate—ankylosing spondylitis	0.000174	0.00289	CcSEcCtD
Captopril—Cardiac arrest—Prednisone—ankylosing spondylitis	0.000174	0.00289	CcSEcCtD
Captopril—Renal failure acute—Methotrexate—ankylosing spondylitis	0.000166	0.00275	CcSEcCtD
Captopril—Weight decreased—Dexamethasone—ankylosing spondylitis	0.000164	0.00273	CcSEcCtD
Captopril—Weight decreased—Betamethasone—ankylosing spondylitis	0.000164	0.00273	CcSEcCtD
Captopril—Dermatitis exfoliative—Methotrexate—ankylosing spondylitis	0.000162	0.00269	CcSEcCtD
Captopril—Muscular weakness—Prednisone—ankylosing spondylitis	0.000162	0.00268	CcSEcCtD
Captopril—Rhinitis—Triamcinolone—ankylosing spondylitis	0.000161	0.00266	CcSEcCtD
Captopril—Rhinitis—Methylprednisolone—ankylosing spondylitis	0.00016	0.00266	CcSEcCtD
Captopril—Hallucination—Methylprednisolone—ankylosing spondylitis	0.000159	0.00264	CcSEcCtD
Captopril—Pharyngitis—Triamcinolone—ankylosing spondylitis	0.000159	0.00264	CcSEcCtD
Captopril—Anaphylactoid reaction—Methotrexate—ankylosing spondylitis	0.000158	0.00262	CcSEcCtD
Captopril—Cerebrovascular accident—Methotrexate—ankylosing spondylitis	0.000156	0.00259	CcSEcCtD
Captopril—Pancreatitis—Prednisone—ankylosing spondylitis	0.000155	0.00257	CcSEcCtD
Captopril—MMP9—Assembly of collagen fibrils and other multimeric structures—MMP3—ankylosing spondylitis	0.000152	0.0265	CbGpPWpGaD
Captopril—MMP2—Degradation of the extracellular matrix—MMP3—ankylosing spondylitis	0.000151	0.0263	CbGpPWpGaD
Captopril—Neutropenia—Prednisone—ankylosing spondylitis	0.000148	0.00245	CcSEcCtD
Captopril—Erectile dysfunction—Prednisone—ankylosing spondylitis	0.000146	0.00242	CcSEcCtD
Captopril—Hallucination—Betamethasone—ankylosing spondylitis	0.000145	0.0024	CcSEcCtD
Captopril—Hallucination—Dexamethasone—ankylosing spondylitis	0.000145	0.0024	CcSEcCtD
Captopril—Ataxia—Methotrexate—ankylosing spondylitis	0.000144	0.00239	CcSEcCtD
Captopril—Weight decreased—Prednisone—ankylosing spondylitis	0.000143	0.00237	CcSEcCtD
Captopril—Vision blurred—Prednisolone—ankylosing spondylitis	0.000143	0.00237	CcSEcCtD
Captopril—Ill-defined disorder—Prednisolone—ankylosing spondylitis	0.000141	0.00233	CcSEcCtD
Captopril—Angioedema—Prednisolone—ankylosing spondylitis	0.000139	0.0023	CcSEcCtD
Captopril—Malaise—Prednisolone—ankylosing spondylitis	0.000137	0.00227	CcSEcCtD
Captopril—Dysgeusia—Triamcinolone—ankylosing spondylitis	0.000137	0.00227	CcSEcCtD
Captopril—Syncope—Prednisolone—ankylosing spondylitis	0.000136	0.00226	CcSEcCtD
Captopril—Loss of consciousness—Prednisolone—ankylosing spondylitis	0.000133	0.00221	CcSEcCtD
Captopril—Eosinophilia—Methotrexate—ankylosing spondylitis	0.000131	0.00217	CcSEcCtD
Captopril—Pancreatitis—Methotrexate—ankylosing spondylitis	0.00013	0.00215	CcSEcCtD
Captopril—Ill-defined disorder—Triamcinolone—ankylosing spondylitis	0.00013	0.00215	CcSEcCtD
Captopril—Ill-defined disorder—Methylprednisolone—ankylosing spondylitis	0.000129	0.00214	CcSEcCtD
Captopril—MMP2—Matrix Metalloproteinases—TNF—ankylosing spondylitis	0.000129	0.0224	CbGpPWpGaD
Captopril—Alopecia—Betamethasone—ankylosing spondylitis	0.000129	0.00213	CcSEcCtD
Captopril—Alopecia—Dexamethasone—ankylosing spondylitis	0.000129	0.00213	CcSEcCtD
Captopril—Discomfort—Prednisolone—ankylosing spondylitis	0.000128	0.00212	CcSEcCtD
Captopril—Angioedema—Triamcinolone—ankylosing spondylitis	0.000128	0.00211	CcSEcCtD
Captopril—Angioedema—Methylprednisolone—ankylosing spondylitis	0.000127	0.00211	CcSEcCtD
Captopril—Hallucination—Prednisone—ankylosing spondylitis	0.000126	0.00209	CcSEcCtD
Captopril—Malaise—Triamcinolone—ankylosing spondylitis	0.000126	0.00209	CcSEcCtD
Captopril—Pancytopenia—Methotrexate—ankylosing spondylitis	0.000126	0.00208	CcSEcCtD
Captopril—Malaise—Methylprednisolone—ankylosing spondylitis	0.000126	0.00208	CcSEcCtD
Captopril—Syncope—Triamcinolone—ankylosing spondylitis	0.000125	0.00208	CcSEcCtD
Captopril—Syncope—Methylprednisolone—ankylosing spondylitis	0.000125	0.00207	CcSEcCtD
Captopril—Anaphylactic shock—Prednisolone—ankylosing spondylitis	0.000124	0.00205	CcSEcCtD
Captopril—Neutropenia—Methotrexate—ankylosing spondylitis	0.000124	0.00205	CcSEcCtD
Captopril—Loss of consciousness—Triamcinolone—ankylosing spondylitis	0.000123	0.00203	CcSEcCtD
Captopril—Loss of consciousness—Methylprednisolone—ankylosing spondylitis	0.000122	0.00203	CcSEcCtD
Captopril—MMP2—amb2 Integrin signaling—TNF—ankylosing spondylitis	0.000122	0.0213	CbGpPWpGaD
Captopril—Shock—Prednisolone—ankylosing spondylitis	0.000122	0.00202	CcSEcCtD
Captopril—Erectile dysfunction—Methotrexate—ankylosing spondylitis	0.000122	0.00202	CcSEcCtD
Captopril—Cough—Triamcinolone—ankylosing spondylitis	0.000122	0.00202	CcSEcCtD
Captopril—REN—Metabolism of proteins—B3GNT2—ankylosing spondylitis	0.000122	0.0212	CbGpPWpGaD
Captopril—Tachycardia—Prednisolone—ankylosing spondylitis	0.000121	0.002	CcSEcCtD
Captopril—Photosensitivity reaction—Methotrexate—ankylosing spondylitis	0.000121	0.002	CcSEcCtD
Captopril—Myalgia—Triamcinolone—ankylosing spondylitis	0.000119	0.00197	CcSEcCtD
Captopril—Myalgia—Methylprednisolone—ankylosing spondylitis	0.000119	0.00197	CcSEcCtD
Captopril—Arthralgia—Methylprednisolone—ankylosing spondylitis	0.000119	0.00197	CcSEcCtD
Captopril—Flushing—Prednisone—ankylosing spondylitis	0.000118	0.00195	CcSEcCtD
Captopril—Ill-defined disorder—Betamethasone—ankylosing spondylitis	0.000118	0.00195	CcSEcCtD
Captopril—Ill-defined disorder—Dexamethasone—ankylosing spondylitis	0.000118	0.00195	CcSEcCtD
Captopril—Discomfort—Triamcinolone—ankylosing spondylitis	0.000117	0.00195	CcSEcCtD
Captopril—Discomfort—Methylprednisolone—ankylosing spondylitis	0.000117	0.00194	CcSEcCtD
Captopril—Stevens-Johnson syndrome—Methotrexate—ankylosing spondylitis	0.000117	0.00194	CcSEcCtD
Captopril—Dry mouth—Triamcinolone—ankylosing spondylitis	0.000116	0.00193	CcSEcCtD
Captopril—Renal failure—Methotrexate—ankylosing spondylitis	0.000116	0.00192	CcSEcCtD
Captopril—Angioedema—Betamethasone—ankylosing spondylitis	0.000116	0.00192	CcSEcCtD
Captopril—Angioedema—Dexamethasone—ankylosing spondylitis	0.000116	0.00192	CcSEcCtD
Captopril—Stomatitis—Methotrexate—ankylosing spondylitis	0.000115	0.00191	CcSEcCtD
Captopril—Confusional state—Methylprednisolone—ankylosing spondylitis	0.000115	0.0019	CcSEcCtD
Captopril—Malaise—Dexamethasone—ankylosing spondylitis	0.000114	0.00189	CcSEcCtD
Captopril—Malaise—Betamethasone—ankylosing spondylitis	0.000114	0.00189	CcSEcCtD
Captopril—Anaphylactic shock—Triamcinolone—ankylosing spondylitis	0.000114	0.00189	CcSEcCtD
Captopril—Anaphylactic shock—Methylprednisolone—ankylosing spondylitis	0.000114	0.00188	CcSEcCtD
Captopril—Syncope—Dexamethasone—ankylosing spondylitis	0.000114	0.00188	CcSEcCtD
Captopril—Syncope—Betamethasone—ankylosing spondylitis	0.000114	0.00188	CcSEcCtD
Captopril—MMP9—AP-1 transcription factor network—IL10—ankylosing spondylitis	0.000113	0.0196	CbGpPWpGaD
Captopril—Shock—Triamcinolone—ankylosing spondylitis	0.000112	0.00186	CcSEcCtD
Captopril—Insomnia—Prednisolone—ankylosing spondylitis	0.000112	0.00186	CcSEcCtD
Captopril—Alopecia—Prednisone—ankylosing spondylitis	0.000112	0.00186	CcSEcCtD
Captopril—Shock—Methylprednisolone—ankylosing spondylitis	0.000112	0.00185	CcSEcCtD
Captopril—Loss of consciousness—Betamethasone—ankylosing spondylitis	0.000111	0.00185	CcSEcCtD
Captopril—Loss of consciousness—Dexamethasone—ankylosing spondylitis	0.000111	0.00185	CcSEcCtD
Captopril—Paraesthesia—Prednisolone—ankylosing spondylitis	0.000111	0.00184	CcSEcCtD
Captopril—Tachycardia—Triamcinolone—ankylosing spondylitis	0.000111	0.00184	CcSEcCtD
Captopril—Tachycardia—Methylprednisolone—ankylosing spondylitis	0.000111	0.00184	CcSEcCtD
Captopril—Agranulocytosis—Methotrexate—ankylosing spondylitis	0.00011	0.00182	CcSEcCtD
Captopril—Myalgia—Dexamethasone—ankylosing spondylitis	0.000108	0.00179	CcSEcCtD
Captopril—Myalgia—Betamethasone—ankylosing spondylitis	0.000108	0.00179	CcSEcCtD
Captopril—Discomfort—Dexamethasone—ankylosing spondylitis	0.000107	0.00177	CcSEcCtD
Captopril—Discomfort—Betamethasone—ankylosing spondylitis	0.000107	0.00177	CcSEcCtD
Captopril—Hypotension—Methylprednisolone—ankylosing spondylitis	0.000106	0.00176	CcSEcCtD
Captopril—Hepatitis—Methotrexate—ankylosing spondylitis	0.000106	0.00176	CcSEcCtD
Captopril—Pharyngitis—Methotrexate—ankylosing spondylitis	0.000105	0.00174	CcSEcCtD
Captopril—Vision blurred—Prednisone—ankylosing spondylitis	0.000104	0.00172	CcSEcCtD
Captopril—Musculoskeletal discomfort—Triamcinolone—ankylosing spondylitis	0.000104	0.00172	CcSEcCtD
Captopril—Musculoskeletal discomfort—Methylprednisolone—ankylosing spondylitis	0.000104	0.00172	CcSEcCtD
Captopril—MMP9—Collagen formation—MMP3—ankylosing spondylitis	0.000104	0.0181	CbGpPWpGaD
Captopril—Anaphylactic shock—Betamethasone—ankylosing spondylitis	0.000103	0.00171	CcSEcCtD
Captopril—Anaphylactic shock—Dexamethasone—ankylosing spondylitis	0.000103	0.00171	CcSEcCtD
Captopril—Insomnia—Triamcinolone—ankylosing spondylitis	0.000103	0.00171	CcSEcCtD
Captopril—Insomnia—Methylprednisolone—ankylosing spondylitis	0.000103	0.0017	CcSEcCtD
Captopril—Ill-defined disorder—Prednisone—ankylosing spondylitis	0.000102	0.0017	CcSEcCtD
Captopril—Paraesthesia—Triamcinolone—ankylosing spondylitis	0.000102	0.0017	CcSEcCtD
Captopril—Feeling abnormal—Prednisolone—ankylosing spondylitis	0.000102	0.00169	CcSEcCtD
Captopril—Paraesthesia—Methylprednisolone—ankylosing spondylitis	0.000102	0.00169	CcSEcCtD
Captopril—Anaemia—Prednisone—ankylosing spondylitis	0.000102	0.00169	CcSEcCtD
Captopril—Shock—Betamethasone—ankylosing spondylitis	0.000102	0.00169	CcSEcCtD
Captopril—Shock—Dexamethasone—ankylosing spondylitis	0.000102	0.00169	CcSEcCtD
Captopril—Dyspnoea—Triamcinolone—ankylosing spondylitis	0.000102	0.00168	CcSEcCtD
Captopril—Thrombocytopenia—Betamethasone—ankylosing spondylitis	0.000101	0.00168	CcSEcCtD
Captopril—Thrombocytopenia—Dexamethasone—ankylosing spondylitis	0.000101	0.00168	CcSEcCtD
Captopril—Tachycardia—Betamethasone—ankylosing spondylitis	0.000101	0.00167	CcSEcCtD
Captopril—Tachycardia—Dexamethasone—ankylosing spondylitis	0.000101	0.00167	CcSEcCtD
Captopril—Angioedema—Prednisone—ankylosing spondylitis	0.000101	0.00167	CcSEcCtD
Captopril—Dyspepsia—Triamcinolone—ankylosing spondylitis	0.0001	0.00166	CcSEcCtD
Captopril—Erythema multiforme—Methotrexate—ankylosing spondylitis	0.0001	0.00166	CcSEcCtD
Captopril—Dyspepsia—Methylprednisolone—ankylosing spondylitis	0.0001	0.00166	CcSEcCtD
Captopril—Malaise—Prednisone—ankylosing spondylitis	9.95e-05	0.00165	CcSEcCtD
Captopril—MMP9—AP-1 transcription factor network—HLA-A—ankylosing spondylitis	9.93e-05	0.0173	CbGpPWpGaD
Captopril—Syncope—Prednisone—ankylosing spondylitis	9.89e-05	0.00164	CcSEcCtD
Captopril—MMP9—Degradation of the extracellular matrix—MMP3—ankylosing spondylitis	9.89e-05	0.0172	CbGpPWpGaD
Captopril—Anorexia—Betamethasone—ankylosing spondylitis	9.85e-05	0.00163	CcSEcCtD
Captopril—Anorexia—Dexamethasone—ankylosing spondylitis	9.85e-05	0.00163	CcSEcCtD
Captopril—Fatigue—Triamcinolone—ankylosing spondylitis	9.82e-05	0.00163	CcSEcCtD
Captopril—Fatigue—Methylprednisolone—ankylosing spondylitis	9.8e-05	0.00162	CcSEcCtD
Captopril—Loss of consciousness—Prednisone—ankylosing spondylitis	9.69e-05	0.00161	CcSEcCtD
Captopril—Hypotension—Dexamethasone—ankylosing spondylitis	9.66e-05	0.0016	CcSEcCtD
Captopril—Hypotension—Betamethasone—ankylosing spondylitis	9.66e-05	0.0016	CcSEcCtD
Captopril—F2—Vitamin B12 Metabolism—CRP—ankylosing spondylitis	9.42e-05	0.0164	CbGpPWpGaD
Captopril—Musculoskeletal discomfort—Dexamethasone—ankylosing spondylitis	9.42e-05	0.00156	CcSEcCtD
Captopril—Musculoskeletal discomfort—Betamethasone—ankylosing spondylitis	9.42e-05	0.00156	CcSEcCtD
Captopril—Myalgia—Prednisone—ankylosing spondylitis	9.39e-05	0.00156	CcSEcCtD
Captopril—Arthralgia—Prednisone—ankylosing spondylitis	9.39e-05	0.00156	CcSEcCtD
Captopril—Feeling abnormal—Triamcinolone—ankylosing spondylitis	9.39e-05	0.00156	CcSEcCtD
Captopril—Feeling abnormal—Methylprednisolone—ankylosing spondylitis	9.37e-05	0.00155	CcSEcCtD
Captopril—Alopecia—Methotrexate—ankylosing spondylitis	9.36e-05	0.00155	CcSEcCtD
Captopril—Insomnia—Betamethasone—ankylosing spondylitis	9.35e-05	0.00155	CcSEcCtD
Captopril—Insomnia—Dexamethasone—ankylosing spondylitis	9.35e-05	0.00155	CcSEcCtD
Captopril—Gastrointestinal pain—Methylprednisolone—ankylosing spondylitis	9.29e-05	0.00154	CcSEcCtD
Captopril—Paraesthesia—Betamethasone—ankylosing spondylitis	9.28e-05	0.00154	CcSEcCtD
Captopril—Paraesthesia—Dexamethasone—ankylosing spondylitis	9.28e-05	0.00154	CcSEcCtD
Captopril—Discomfort—Prednisone—ankylosing spondylitis	9.28e-05	0.00154	CcSEcCtD
Captopril—Dyspepsia—Betamethasone—ankylosing spondylitis	9.1e-05	0.00151	CcSEcCtD
Captopril—Dyspepsia—Dexamethasone—ankylosing spondylitis	9.1e-05	0.00151	CcSEcCtD
Captopril—Dysgeusia—Methotrexate—ankylosing spondylitis	9.03e-05	0.0015	CcSEcCtD
Captopril—Body temperature increased—Triamcinolone—ankylosing spondylitis	9e-05	0.00149	CcSEcCtD
Captopril—Anaphylactic shock—Prednisone—ankylosing spondylitis	9e-05	0.00149	CcSEcCtD
Captopril—Abdominal pain—Methylprednisolone—ankylosing spondylitis	8.98e-05	0.00149	CcSEcCtD
Captopril—Decreased appetite—Dexamethasone—ankylosing spondylitis	8.98e-05	0.00149	CcSEcCtD
Captopril—Decreased appetite—Betamethasone—ankylosing spondylitis	8.98e-05	0.00149	CcSEcCtD
Captopril—Fatigue—Betamethasone—ankylosing spondylitis	8.91e-05	0.00148	CcSEcCtD
Captopril—Fatigue—Dexamethasone—ankylosing spondylitis	8.91e-05	0.00148	CcSEcCtD
Captopril—Shock—Prednisone—ankylosing spondylitis	8.86e-05	0.00147	CcSEcCtD
Captopril—Tachycardia—Prednisone—ankylosing spondylitis	8.78e-05	0.00146	CcSEcCtD
Captopril—Vision blurred—Methotrexate—ankylosing spondylitis	8.69e-05	0.00144	CcSEcCtD
Captopril—Anorexia—Prednisone—ankylosing spondylitis	8.58e-05	0.00142	CcSEcCtD
Captopril—MMP2—Angiopoietin receptor Tie2-mediated signaling—TNF—ankylosing spondylitis	8.55e-05	0.0149	CbGpPWpGaD
Captopril—Ill-defined disorder—Methotrexate—ankylosing spondylitis	8.55e-05	0.00142	CcSEcCtD
Captopril—Anaemia—Methotrexate—ankylosing spondylitis	8.52e-05	0.00141	CcSEcCtD
Captopril—Feeling abnormal—Dexamethasone—ankylosing spondylitis	8.52e-05	0.00141	CcSEcCtD
Captopril—Feeling abnormal—Betamethasone—ankylosing spondylitis	8.52e-05	0.00141	CcSEcCtD
Captopril—Gastrointestinal pain—Dexamethasone—ankylosing spondylitis	8.45e-05	0.0014	CcSEcCtD
Captopril—Gastrointestinal pain—Betamethasone—ankylosing spondylitis	8.45e-05	0.0014	CcSEcCtD
Captopril—MMP9—Matrix Metalloproteinases—TNF—ankylosing spondylitis	8.44e-05	0.0147	CbGpPWpGaD
Captopril—Malaise—Methotrexate—ankylosing spondylitis	8.31e-05	0.00138	CcSEcCtD
Captopril—Musculoskeletal discomfort—Prednisone—ankylosing spondylitis	8.2e-05	0.00136	CcSEcCtD
Captopril—Dizziness—Prednisolone—ankylosing spondylitis	8.19e-05	0.00136	CcSEcCtD
Captopril—Asthenia—Triamcinolone—ankylosing spondylitis	8.17e-05	0.00135	CcSEcCtD
Captopril—Abdominal pain—Betamethasone—ankylosing spondylitis	8.17e-05	0.00135	CcSEcCtD
Captopril—Abdominal pain—Dexamethasone—ankylosing spondylitis	8.17e-05	0.00135	CcSEcCtD
Captopril—Body temperature increased—Dexamethasone—ankylosing spondylitis	8.17e-05	0.00135	CcSEcCtD
Captopril—Body temperature increased—Betamethasone—ankylosing spondylitis	8.17e-05	0.00135	CcSEcCtD
Captopril—Asthenia—Methylprednisolone—ankylosing spondylitis	8.15e-05	0.00135	CcSEcCtD
Captopril—Insomnia—Prednisone—ankylosing spondylitis	8.14e-05	0.00135	CcSEcCtD
Captopril—Paraesthesia—Prednisone—ankylosing spondylitis	8.08e-05	0.00134	CcSEcCtD
Captopril—Pruritus—Triamcinolone—ankylosing spondylitis	8.06e-05	0.00134	CcSEcCtD
Captopril—Cough—Methotrexate—ankylosing spondylitis	8.04e-05	0.00133	CcSEcCtD
Captopril—Pruritus—Methylprednisolone—ankylosing spondylitis	8.04e-05	0.00133	CcSEcCtD
Captopril—MMP9—amb2 Integrin signaling—TNF—ankylosing spondylitis	8.02e-05	0.014	CbGpPWpGaD
Captopril—Dyspepsia—Prednisone—ankylosing spondylitis	7.92e-05	0.00131	CcSEcCtD
Captopril—Arthralgia—Methotrexate—ankylosing spondylitis	7.85e-05	0.0013	CcSEcCtD
Captopril—Chest pain—Methotrexate—ankylosing spondylitis	7.85e-05	0.0013	CcSEcCtD
Captopril—Myalgia—Methotrexate—ankylosing spondylitis	7.85e-05	0.0013	CcSEcCtD
Captopril—Decreased appetite—Prednisone—ankylosing spondylitis	7.82e-05	0.0013	CcSEcCtD
Captopril—Rash—Prednisolone—ankylosing spondylitis	7.81e-05	0.00129	CcSEcCtD
Captopril—Dermatitis—Prednisolone—ankylosing spondylitis	7.8e-05	0.00129	CcSEcCtD
Captopril—Diarrhoea—Methylprednisolone—ankylosing spondylitis	7.78e-05	0.00129	CcSEcCtD
Captopril—Fatigue—Prednisone—ankylosing spondylitis	7.76e-05	0.00129	CcSEcCtD
Captopril—Headache—Prednisolone—ankylosing spondylitis	7.76e-05	0.00129	CcSEcCtD
Captopril—SLC15A1—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	7.76e-05	0.0135	CbGpPWpGaD
Captopril—Discomfort—Methotrexate—ankylosing spondylitis	7.75e-05	0.00129	CcSEcCtD
Captopril—Constipation—Prednisone—ankylosing spondylitis	7.7e-05	0.00128	CcSEcCtD
Captopril—F2—Folate Metabolism—CRP—ankylosing spondylitis	7.66e-05	0.0134	CbGpPWpGaD
Captopril—Confusional state—Methotrexate—ankylosing spondylitis	7.59e-05	0.00126	CcSEcCtD
Captopril—LTA4H—Metabolism—B3GNT2—ankylosing spondylitis	7.57e-05	0.0132	CbGpPWpGaD
Captopril—Dizziness—Triamcinolone—ankylosing spondylitis	7.53e-05	0.00125	CcSEcCtD
Captopril—Anaphylactic shock—Methotrexate—ankylosing spondylitis	7.52e-05	0.00125	CcSEcCtD
Captopril—Dizziness—Methylprednisolone—ankylosing spondylitis	7.52e-05	0.00125	CcSEcCtD
Captopril—MMP9—Spinal Cord Injury—IL1A—ankylosing spondylitis	7.46e-05	0.013	CbGpPWpGaD
Captopril—Feeling abnormal—Prednisone—ankylosing spondylitis	7.42e-05	0.00123	CcSEcCtD
Captopril—Asthenia—Dexamethasone—ankylosing spondylitis	7.42e-05	0.00123	CcSEcCtD
Captopril—Asthenia—Betamethasone—ankylosing spondylitis	7.42e-05	0.00123	CcSEcCtD
Captopril—Thrombocytopenia—Methotrexate—ankylosing spondylitis	7.37e-05	0.00122	CcSEcCtD
Captopril—Gastrointestinal pain—Prednisone—ankylosing spondylitis	7.36e-05	0.00122	CcSEcCtD
Captopril—Nausea—Prednisolone—ankylosing spondylitis	7.36e-05	0.00122	CcSEcCtD
Captopril—Pruritus—Dexamethasone—ankylosing spondylitis	7.31e-05	0.00121	CcSEcCtD
Captopril—Pruritus—Betamethasone—ankylosing spondylitis	7.31e-05	0.00121	CcSEcCtD
Captopril—Vomiting—Triamcinolone—ankylosing spondylitis	7.24e-05	0.0012	CcSEcCtD
Captopril—Vomiting—Methylprednisolone—ankylosing spondylitis	7.23e-05	0.0012	CcSEcCtD
Captopril—Rash—Triamcinolone—ankylosing spondylitis	7.18e-05	0.00119	CcSEcCtD
Captopril—Dermatitis—Triamcinolone—ankylosing spondylitis	7.18e-05	0.00119	CcSEcCtD
Captopril—Anorexia—Methotrexate—ankylosing spondylitis	7.17e-05	0.00119	CcSEcCtD
Captopril—Rash—Methylprednisolone—ankylosing spondylitis	7.17e-05	0.00119	CcSEcCtD
Captopril—Dermatitis—Methylprednisolone—ankylosing spondylitis	7.16e-05	0.00119	CcSEcCtD
Captopril—Headache—Triamcinolone—ankylosing spondylitis	7.14e-05	0.00118	CcSEcCtD
Captopril—Headache—Methylprednisolone—ankylosing spondylitis	7.12e-05	0.00118	CcSEcCtD
Captopril—Abdominal pain—Prednisone—ankylosing spondylitis	7.12e-05	0.00118	CcSEcCtD
Captopril—Body temperature increased—Prednisone—ankylosing spondylitis	7.12e-05	0.00118	CcSEcCtD
Captopril—Diarrhoea—Betamethasone—ankylosing spondylitis	7.07e-05	0.00117	CcSEcCtD
Captopril—Diarrhoea—Dexamethasone—ankylosing spondylitis	7.07e-05	0.00117	CcSEcCtD
Captopril—Hypotension—Methotrexate—ankylosing spondylitis	7.03e-05	0.00117	CcSEcCtD
Captopril—Musculoskeletal discomfort—Methotrexate—ankylosing spondylitis	6.85e-05	0.00114	CcSEcCtD
Captopril—Dizziness—Betamethasone—ankylosing spondylitis	6.83e-05	0.00113	CcSEcCtD
Captopril—Dizziness—Dexamethasone—ankylosing spondylitis	6.83e-05	0.00113	CcSEcCtD
Captopril—Insomnia—Methotrexate—ankylosing spondylitis	6.8e-05	0.00113	CcSEcCtD
Captopril—Nausea—Triamcinolone—ankylosing spondylitis	6.77e-05	0.00112	CcSEcCtD
Captopril—Paraesthesia—Methotrexate—ankylosing spondylitis	6.75e-05	0.00112	CcSEcCtD
Captopril—Nausea—Methylprednisolone—ankylosing spondylitis	6.75e-05	0.00112	CcSEcCtD
Captopril—Dyspnoea—Methotrexate—ankylosing spondylitis	6.71e-05	0.00111	CcSEcCtD
Captopril—Somnolence—Methotrexate—ankylosing spondylitis	6.69e-05	0.00111	CcSEcCtD
Captopril—Dyspepsia—Methotrexate—ankylosing spondylitis	6.62e-05	0.0011	CcSEcCtD
Captopril—Vomiting—Betamethasone—ankylosing spondylitis	6.57e-05	0.00109	CcSEcCtD
Captopril—Vomiting—Dexamethasone—ankylosing spondylitis	6.57e-05	0.00109	CcSEcCtD
Captopril—Decreased appetite—Methotrexate—ankylosing spondylitis	6.54e-05	0.00108	CcSEcCtD
Captopril—Rash—Dexamethasone—ankylosing spondylitis	6.52e-05	0.00108	CcSEcCtD
Captopril—Rash—Betamethasone—ankylosing spondylitis	6.52e-05	0.00108	CcSEcCtD
Captopril—Dermatitis—Dexamethasone—ankylosing spondylitis	6.51e-05	0.00108	CcSEcCtD
Captopril—Dermatitis—Betamethasone—ankylosing spondylitis	6.51e-05	0.00108	CcSEcCtD
Captopril—Fatigue—Methotrexate—ankylosing spondylitis	6.49e-05	0.00108	CcSEcCtD
Captopril—Headache—Betamethasone—ankylosing spondylitis	6.48e-05	0.00107	CcSEcCtD
Captopril—Headache—Dexamethasone—ankylosing spondylitis	6.48e-05	0.00107	CcSEcCtD
Captopril—Asthenia—Prednisone—ankylosing spondylitis	6.46e-05	0.00107	CcSEcCtD
Captopril—F2—Post-translational protein modification—B3GNT2—ankylosing spondylitis	6.45e-05	0.0112	CbGpPWpGaD
Captopril—MMP9—TWEAK Signaling Pathway—TNF—ankylosing spondylitis	6.45e-05	0.0112	CbGpPWpGaD
Captopril—Pruritus—Prednisone—ankylosing spondylitis	6.37e-05	0.00106	CcSEcCtD
Captopril—MMP2—Extracellular matrix organization—MMP3—ankylosing spondylitis	6.32e-05	0.011	CbGpPWpGaD
Captopril—Feeling abnormal—Methotrexate—ankylosing spondylitis	6.2e-05	0.00103	CcSEcCtD
Captopril—Diarrhoea—Prednisone—ankylosing spondylitis	6.16e-05	0.00102	CcSEcCtD
Captopril—Gastrointestinal pain—Methotrexate—ankylosing spondylitis	6.15e-05	0.00102	CcSEcCtD
Captopril—Nausea—Betamethasone—ankylosing spondylitis	6.14e-05	0.00102	CcSEcCtD
Captopril—Nausea—Dexamethasone—ankylosing spondylitis	6.14e-05	0.00102	CcSEcCtD
Captopril—F2—Selenium Micronutrient Network—CRP—ankylosing spondylitis	6.09e-05	0.0106	CbGpPWpGaD
Captopril—MMP2—Metabolism of proteins—B3GNT2—ankylosing spondylitis	6.05e-05	0.0105	CbGpPWpGaD
Captopril—MMP9—Spinal Cord Injury—TLR4—ankylosing spondylitis	5.98e-05	0.0104	CbGpPWpGaD
Captopril—Dizziness—Prednisone—ankylosing spondylitis	5.95e-05	0.000987	CcSEcCtD
Captopril—Abdominal pain—Methotrexate—ankylosing spondylitis	5.95e-05	0.000986	CcSEcCtD
Captopril—Body temperature increased—Methotrexate—ankylosing spondylitis	5.95e-05	0.000986	CcSEcCtD
Captopril—SLC22A6—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	5.76e-05	0.01	CbGpPWpGaD
Captopril—Vomiting—Prednisone—ankylosing spondylitis	5.72e-05	0.000949	CcSEcCtD
Captopril—Rash—Prednisone—ankylosing spondylitis	5.68e-05	0.000941	CcSEcCtD
Captopril—Dermatitis—Prednisone—ankylosing spondylitis	5.67e-05	0.00094	CcSEcCtD
Captopril—Headache—Prednisone—ankylosing spondylitis	5.64e-05	0.000935	CcSEcCtD
Captopril—ACE—Metabolism of proteins—B3GNT2—ankylosing spondylitis	5.44e-05	0.00948	CbGpPWpGaD
Captopril—Asthenia—Methotrexate—ankylosing spondylitis	5.4e-05	0.000895	CcSEcCtD
Captopril—Nausea—Prednisone—ankylosing spondylitis	5.35e-05	0.000886	CcSEcCtD
Captopril—Pruritus—Methotrexate—ankylosing spondylitis	5.32e-05	0.000882	CcSEcCtD
Captopril—Diarrhoea—Methotrexate—ankylosing spondylitis	5.15e-05	0.000853	CcSEcCtD
Captopril—Dizziness—Methotrexate—ankylosing spondylitis	4.97e-05	0.000825	CcSEcCtD
Captopril—Vomiting—Methotrexate—ankylosing spondylitis	4.78e-05	0.000793	CcSEcCtD
Captopril—Rash—Methotrexate—ankylosing spondylitis	4.74e-05	0.000786	CcSEcCtD
Captopril—Dermatitis—Methotrexate—ankylosing spondylitis	4.74e-05	0.000786	CcSEcCtD
Captopril—Headache—Methotrexate—ankylosing spondylitis	4.71e-05	0.000781	CcSEcCtD
Captopril—Nausea—Methotrexate—ankylosing spondylitis	4.47e-05	0.000741	CcSEcCtD
Captopril—ABCB1—Allograft Rejection—HLA-C—ankylosing spondylitis	4.41e-05	0.0077	CbGpPWpGaD
Captopril—F2—Angiopoietin receptor Tie2-mediated signaling—TNF—ankylosing spondylitis	4.33e-05	0.00755	CbGpPWpGaD
Captopril—F2—Vitamin B12 Metabolism—TNF—ankylosing spondylitis	4.26e-05	0.00743	CbGpPWpGaD
Captopril—MMP9—Extracellular matrix organization—MMP3—ankylosing spondylitis	4.14e-05	0.00722	CbGpPWpGaD
Captopril—ABCB1—Allograft Rejection—IL17A—ankylosing spondylitis	4.04e-05	0.00704	CbGpPWpGaD
Captopril—F2—Class A/1 (Rhodopsin-like receptors)—PTGER4—ankylosing spondylitis	3.92e-05	0.00683	CbGpPWpGaD
Captopril—F2—Gastrin-CREB signalling pathway via PKC and MAPK—MMP3—ankylosing spondylitis	3.77e-05	0.00657	CbGpPWpGaD
Captopril—ABCB1—Allograft Rejection—IL12B—ankylosing spondylitis	3.75e-05	0.00654	CbGpPWpGaD
Captopril—ALB—Vitamin B12 Metabolism—CRP—ankylosing spondylitis	3.74e-05	0.00652	CbGpPWpGaD
Captopril—F2—Folate Metabolism—TNF—ankylosing spondylitis	3.47e-05	0.00605	CbGpPWpGaD
Captopril—F2—Metabolism of proteins—B3GNT2—ankylosing spondylitis	3.06e-05	0.00534	CbGpPWpGaD
Captopril—ALB—Folate Metabolism—CRP—ankylosing spondylitis	3.04e-05	0.0053	CbGpPWpGaD
Captopril—ALB—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	2.99e-05	0.00522	CbGpPWpGaD
Captopril—F2—GPCR ligand binding—PTGER4—ankylosing spondylitis	2.99e-05	0.0052	CbGpPWpGaD
Captopril—MMP9—Spinal Cord Injury—TNF—ankylosing spondylitis	2.82e-05	0.00492	CbGpPWpGaD
Captopril—ABCB1—Allograft Rejection—IL1A—ankylosing spondylitis	2.76e-05	0.00481	CbGpPWpGaD
Captopril—F2—Selenium Micronutrient Network—TNF—ankylosing spondylitis	2.76e-05	0.00481	CbGpPWpGaD
Captopril—ABCB1—Allograft Rejection—IL10—ankylosing spondylitis	2.74e-05	0.00479	CbGpPWpGaD
Captopril—ABCB1—Allograft Rejection—CD40LG—ankylosing spondylitis	2.74e-05	0.00479	CbGpPWpGaD
Captopril—ABCB1—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	2.62e-05	0.00457	CbGpPWpGaD
Captopril—ABCB1—Allograft Rejection—HLA-B—ankylosing spondylitis	2.61e-05	0.00455	CbGpPWpGaD
Captopril—ABCB1—Allograft Rejection—HLA-A—ankylosing spondylitis	2.42e-05	0.00422	CbGpPWpGaD
Captopril—ALB—Selenium Micronutrient Network—CRP—ankylosing spondylitis	2.42e-05	0.00421	CbGpPWpGaD
Captopril—ALB—Vitamin B12 Metabolism—TNF—ankylosing spondylitis	1.69e-05	0.00295	CbGpPWpGaD
Captopril—F2—GPCR downstream signaling—PTGER4—ankylosing spondylitis	1.69e-05	0.00294	CbGpPWpGaD
Captopril—F2—Signaling by GPCR—PTGER4—ankylosing spondylitis	1.53e-05	0.00267	CbGpPWpGaD
Captopril—ALB—Folate Metabolism—TNF—ankylosing spondylitis	1.38e-05	0.0024	CbGpPWpGaD
Captopril—MMP2—Developmental Biology—TNF—ankylosing spondylitis	1.37e-05	0.00239	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—PTGER4—ankylosing spondylitis	1.17e-05	0.00204	CbGpPWpGaD
Captopril—ALB—Selenium Micronutrient Network—TNF—ankylosing spondylitis	1.09e-05	0.00191	CbGpPWpGaD
Captopril—F2—Signaling by GPCR—MMP3—ankylosing spondylitis	1.09e-05	0.0019	CbGpPWpGaD
Captopril—ABCB1—Allograft Rejection—TNF—ankylosing spondylitis	1.04e-05	0.00182	CbGpPWpGaD
Captopril—F2—Signaling Pathways—PTGER4—ankylosing spondylitis	9.05e-06	0.00158	CbGpPWpGaD
Captopril—MMP9—Developmental Biology—TNF—ankylosing spondylitis	8.98e-06	0.00157	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—MMP3—ankylosing spondylitis	8.35e-06	0.00145	CbGpPWpGaD
Captopril—F2—Signaling Pathways—MMP3—ankylosing spondylitis	6.44e-06	0.00112	CbGpPWpGaD
Captopril—ALB—Metabolism—B3GNT2—ankylosing spondylitis	6.26e-06	0.00109	CbGpPWpGaD
Captopril—ABCB1—Metabolism—B3GNT2—ankylosing spondylitis	5.49e-06	0.000956	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—B3GNT2—ankylosing spondylitis	5.17e-06	0.000901	CbGpPWpGaD
Captopril—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—ankylosing spondylitis	5.16e-06	0.000899	CbGpPWpGaD
